6天8家药企扎堆递表:港股生物医药IPO回暖下的机遇与隐忧 德镁医药销售费用率62%,远超行业35%的中位数水平

21世纪经济报道
Nov 07

炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!   港交所再迎生物医药企业递表的密集期。   10月26日至31日,短短6天内,鼎泰药研、新桥生物、礼邦制药等8家药企相继提交上市申请,在港股市场流动性改善的背景下,这股冲刺热潮既折射出行业对融资窗口的集体把握,也暴露出不同赛道玩家的生存分化与发展焦虑。   此轮药企递表潮的背后,是港股市场环境的显著改善。   高特佳投资...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10